[{"Assets_0_Q2_USD":6573716.0,"CommonStockSharesOutstanding_0_Q2_shares":12545120.0,"EarningsPerShareBasic_1_Q2_USD":-0.11,"EarningsPerShareBasic_2_Q2_USD":-0.19,"EarningsPerShareDiluted_1_Q2_USD":-0.11,"EarningsPerShareDiluted_2_Q2_USD":-0.19,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-2110662.0,"NetIncomeLoss_1_Q2_USD":-1427350.0,"NetIncomeLoss_2_Q2_USD":-2409036.0,"StockholdersEquity_0_Q2_USD":721158.0,"Ticker":"RLMD","CIK":"1553643","name":"RELMADA THERAPEUTICS, INC.","OfficialName":"Relmada Therapeutics Inc. Common Stock","form":"10-Q","period":"20171231","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"772606380.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180212"}]